S&P 500
6,000.36
+1.0%
+$61.06
DJI
42,762.87
+1.0%
+$443.13
NASDAQ
19,529.95
+1.2%
+$231.50
Bitcoin
105,588.00
+1.4%
+1,482.01
AAPL
$204.23
+1.8%
+$3.60
AMZN
$213.68
+2.8%
+$5.77
GOOG
$174.93
+3.0%
+$5.12
META
$698.00
+2.0%
+$13.38
MSFT
$470.38
+0.6%
+$2.70
NVDA
$141.76
+1.3%
+$1.77
TSLA
$295.66
+3.8%
+$10.96
Philip Saglimbeni
PhilipSags
Philip is an avid investor and writer. He contributes to The Motley Fool and Seeking Alpha. You can follow Philip on Twitter @philsags.
Recent Articles by Philip Saglimbeni

Mar 2, 2014
by Philip Saglimbeni
CVS Caremark: Everyone Should Love a Quitter
CVS Caremark made headlines in early February after it announced plans to stop all sales of tobacco products by October. The move is setting the company up to be the undisputed pharmacy leader among health-conscious consumers.

Mar 1, 2014
by Philip Saglimbeni
Why Under Armour's Valuation Doesn't Matter
With a skyrocketing share price, Under Armour has come under fire for having an expensive valuation. However, considering the company's long-term potential, valuation should be cast aside in favor of a superior growth story.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.